Abstract
Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.
| Original language | English |
|---|---|
| Pages (from-to) | 449-454 |
| Number of pages | 6 |
| Journal | Clinical Chemistry and Laboratory Medicine |
| Volume | 50 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2012 |
Fingerprint
Keywords
- community-acquired pneumonia
- gene polymorphism
- metalloproteinase-9 (MMP-9)
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
Cite this
Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. / Chiang, Ting Yen; Shyu, Ling Yuh; Tsao, Thomas Chang Yao; Chien, Ming Hsien; Tsao, Shih Ming; Lee, Yuan Ti; Yang, Shun Fa.
In: Clinical Chemistry and Laboratory Medicine, Vol. 50, No. 3, 01.03.2012, p. 449-454.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia
AU - Chiang, Ting Yen
AU - Shyu, Ling Yuh
AU - Tsao, Thomas Chang Yao
AU - Chien, Ming Hsien
AU - Tsao, Shih Ming
AU - Lee, Yuan Ti
AU - Yang, Shun Fa
PY - 2012/3/1
Y1 - 2012/3/1
N2 - Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.
AB - Background: The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP). Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms. Results: The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95 confident interval: 4.2722.75). Plasma MMP-9 level may act as a prediction marker for CAP. Conclusions: Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.
KW - community-acquired pneumonia
KW - gene polymorphism
KW - metalloproteinase-9 (MMP-9)
UR - http://www.scopus.com/inward/record.url?scp=84860435518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860435518&partnerID=8YFLogxK
U2 - 10.1515/cclm.2011.805
DO - 10.1515/cclm.2011.805
M3 - Article
C2 - 22107133
AN - SCOPUS:84860435518
VL - 50
SP - 449
EP - 454
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
SN - 1434-6621
IS - 3
ER -